HRN001 / Harness Therap - LARVOL DELTA

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board (The Manila Times) - "Preclinical development will continue throughout 2026 to support clinical entry in 2027...The CAB will provide strategic guidance on clinical development, trial design, and translational strategy as the programme advances towards the clinic...Dr Andy Billinton, Chief Scientific Officer of Harness Therapeutics, will present the company's work in HD at the upcoming annual CHDI Huntington’s Disease Therapeutics Conference in Palm Springs, California, 23rd-26th February, providing further insights into the scientific rationale and development progress for HRN001."

New trial • Pipeline update • CNS Disorders • Huntington's Disease

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases (BioSpace) - "Harness Therapeutics...announces that it has successfully raised an additional £4 million in funding from its existing investors, bringing the total invested to £17.6 million. Proceeds will be used to advance Harness’ lead Huntington’s Disease (HD) programme targeting FAN1 nuclease and pursue target discovery and validation activities in other neurodegenerative disease pathways."

Financing • CNS Disorders • Huntington's Disease